During the last session, Phathom Pharmaceuticals Inc (NASDAQ:PHAT)’s traded shares were 1.03 million, with the beta value of the company hitting 0.43. At the end of the trading day, the stock’s price was $6.08, reflecting an intraday gain of 8.96% or $0.5. The 52-week high for the PHAT share is $19.71, that puts it down -224.18 from that peak though still a striking 16.61% gain since the share price plummeted to a 52-week low of $5.07. The company’s market capitalization is $415.74M, and the average trade volume was 1.01 million shares over the past three months.
Phathom Pharmaceuticals Inc (PHAT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.22. PHAT has a Sell rating from 2 analyst(s) out of 10 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 6 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -1.08.
Phathom Pharmaceuticals Inc (NASDAQ:PHAT) trade information
Phathom Pharmaceuticals Inc (PHAT) registered a 8.96% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 8.96% in intraday trading to $6.08, hitting a weekly high. The stock’s 5-day price performance is 5.01%, and it has moved by 7.99% in 30 days. Based on these gigs, the overall price performance for the year is -43.12%.
The consensus price target of analysts on Wall Street is $27, which implies an increase of 77.48% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $12 and $35 respectively. As a result, PHAT is trading at a discount of -475.66% off the target high and -97.37% off the low.
Phathom Pharmaceuticals Inc (PHAT) estimates and forecasts
In the rating firms’ projections, revenue will increase 7,414.06% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 25.65M as predicted by 7 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 28.54M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 682k and 1.91M respectively. In this case, analysts expect current quarter sales to grow by 3,661.58% and then jump by 1,392.80% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -137.06%. While earnings are projected to return -34.71% in 2025, the next five years will return 22.16% per annum.
PHAT Dividends
Phathom Pharmaceuticals Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 7.46 million shares, is of MEDICXI VENTURES MANAGEMENT (JERSEY) LTD’s that is approximately 12.7473% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $76.89 million.
Also, the Mutual Funds coming in first place with the largest holdings of Phathom Pharmaceuticals Inc (PHAT) shares are Invesco Global Fund and PGIM Jennison Health Sciences Fd . Data provided on Oct 31, 2024 indicates that Invesco Global Fund owns about 1.98 shares. This amounts to just over 2.89 percent of the company’s overall shares, with a $12.01 million market value. The same data shows that the other fund manager holds slightly less at 1.78, or about 2.61% of the stock, which is worth about $10.83 million.
